Alaunos Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $2.2M
- Price
- $0.7425
- % Change (Daily % change from the live per-ticker quote feed.)
- -6.64%
- Volume
- 121.4K
About
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.
Quick stats
Shares outstanding2.9M
Computed float2.7M
Float / shares91.7%
Cash runway (months)7.2
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001107421
Websitehttps://www.alaunos.com
AI Summary
AI-generated1/6
minorbearishoffering
Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules
Alaunos Therapeutics priced a registered direct offering of 380,469 common shares plus pre-funded warrants on up to 386,654 additional shares at $1.46 per share, for aggregate gross proceeds of approximately $1.12 million.
The deal was priced at-the-market under Nasdaq rules with Dawson James Securities as sole placement agent and is expected to close on or about September 21, 2026, off an effective Form S-3 shelf.
Proceeds are earmarked for general working capital and corporate purposes — a small but dilutive raise that underscores the micro-cap biotech's ongoing cash needs as it advances its oral obesity candidate ALN1003.
Red flags
- use of proceeds is 'general working capital and corporate purposes' with no specific project named
- very small raise (~$1.12M) suggests a tight cash position for the micro-cap biotech
- pre-funded warrants add near-term dilution equal to roughly half the offering